Get the Stockscreener App
13.50
0.75%
0.10
Exozymes Inc stock is traded at $13.50, with a volume of 3,522.
It is up +0.75% in the last 24 hours and up +23.97% over the past month.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
See More
Previous Close:
$13.40
Open:
$13.48
24h Volume:
3,522
Relative Volume:
0.31
Market Cap:
$112.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.40%
1M Performance:
+23.97%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.30
$13.50
1-Week Range:
$13.23
$15.14
52-Week Range:
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
13.50 | 117.07M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Exozymes Inc Stock (EXOZ) Latest News
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast - ACCESS Newswire
Exozymes (NASDAQ:EXOZ) Issues Quarterly Earnings Results - MarketBeat
eXoZymes Inc. Reports Q1 2025 Highlights and NCTx Launch - TipRanks
Earnings call transcript: eXoZymes Q1 2025 unveils innovation and market strategy - Investing.com Australia
Exozymes Q1 2025 Earnings Call Transcript - MarketBeat
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today - Stock Titan
eXoZymes develops AI-driven approach to produce rare nutraceutical compound - World Bio Market Insights
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST - Stock Titan
eXoZymes Launches Spin-Out, NCTx, To Unlock A Promising Compound For Gut And Liver Health - SynBioBeta
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health - ACCESS Newswire
Revolutionary Liver Health Compound Finally Achievable: How AI Platform Solved 30-Year Production Challenge - Stock Titan
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - ADVFN
eXoZymes creates AI-engineered enzymes for biomanufacturing - Scientific Computing World
eXoZymes Inc. Introduces 'Exozymes' Terminology in Cover Story of GEN Biotechnology to Advance Cell-Free Biomanufacturing - Nasdaq
Bringing clarity and precision to the cell-free space by introducing exozymes | Daily Guardian - dailyguardian.ca
Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Newswire.com
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice - Yahoo Finance
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Tacoma News Tribune
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vic - ACCESS Newswire
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
eXoZymes appoints Damien Perriman as Chief Commercial Officer - World Bio Market Insights
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
eXoZymes Inc. (EXOZ) reports earnings - Quartz
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Big News Network.com
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
Exozymes Inc Stock (EXOZ) Financials Data
There is no financial data for Exozymes Inc (EXOZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):